Loading viewer...
investor_presentation
Format: PDF investor_presentation
Tumor Infiltrating Lymphocyte Cell Therapy for Treatment of Solid Tumors April 2021 © 2021, Iovance Biotherapeutics, Inc 1
Tumor Infiltrating Lymphocyte Cell
Therapy for Treatment of Solid Tumors
© 2021, Iovance Biotherapeutics, Inc 1Forward Looking Statements
2Certain matters discussed inthispresentation are“forward -looking statements” ofIovance Biotherapeutics, Inc,Inc.(hereinafter referred toasthe“Company,” “we,”
“us,” or“our”) within themeaning ofthePrivate Securities Litigation Reform Actof1995 (the“PSLRA”) .Allsuch written ororalstatements made inthispresentation,
other than statements ofhistorical fact, areforward -looking statements andareintended tobecovered bythesafe harbor forforward- looking statements provided by
thePSLRA. Without limiting theforegoing, wemay, insome cases, use terms such as“predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “could,” “might,” “will,” “should” orother words that convey uncertainty offuture events or
outcomes and areintended toidentify forward -looking statements .Forward- looking statements arebased onassumptions and assessments made inlight of
management’s experience andperception ofhistorical trends, current conditions, expected future developments andother factors believed tobeappropriate. Forward-
looking statements inthispress release aremade asofthedate ofthispress release, andweundertake noduty toupdate orrevise anysuch statements, whether as
aresult ofnew information, future events orotherwise. Forward -looking statements arenotguarantees offuture performance andaresubject torisks, uncertainties
andother factors, many ofwhich areoutside ofourcontrol, thatmay cause actual results, levels ofactivity, performance, achievements anddevelopments tobe
materially different from those expressed inorimplied bythese forward -looking statements .Important factors that could cause actual results, developments and
business decisions todiffer materially from forward -looking statements aredescribed inthesections titled “Risk Factors“ inourfilings with theSecurities and
Exchange Commission, including ourmost recent Annual Report onForm 10-KandQuarterly Reports onForm 10-Q,andinclude, butarenotlimited to,thefollowing
substantial known andunknown risks anduncertainties inherent inourbusiness :theeffects oftheCOVID- 19pandemic ;risks related tothetiming ofandourability to
successfully develop, submit, obtain andmaintain U.S.Food andDrug Administration (“FDA”) orother regulatory authority approval of,orother action withrespect to,
ourproduct candidates, and ourability tosuccessfully commercialize anyproduct candidates forwhich weobtain FDA approval ;preliminary and interim clinical
results, which may include efficacy andsafety results, from ongoing clinical trials may notbereflected inthefinal analyses ofourongoing clinical trials orsubgroups
within these trials ;theriskthatenrollment may need tobeadjusted forourtrials andcohorts within those trials based onFDA andother regulatory agency input ;the
Preview truncated — download the full document for the complete content.
investor_presentation
35 Pages
investor_presentation
27 Pages
Yum China Holdings, Inc.
ISG (III) Investor Presentation June 2023
investor_presentationinvestor_presentation
25 Pages
Information Services Group, Inc.